Freenome Raises $300M In Series D Financing To Advance Multiomics Platform For Early Cancer Detection
Freenome Raises $300M In Series D Financing To Advance Multiomics Platform For Early Cancer Detection
12/07/21, 8:00 AM
Location
san franciscoMoney raised
$300 million
Industry
biotechnology
science and engineering
health care
Round Type
series d
Freenome, a privately held biotech company, today announced a Series D funding of $300 million. This brings the company's total financing to over $800 million since the company was founded in 2014.
Company Info
Location
san francisco, california, united states
Additional Info
Freenome is a biotechnology company with a comprehensive multiomics platform for early cancer detection using a routine blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. Freenome is headquartered in South San Francisco, California.
1 Joseph DA, King JB, Dowling NF, Thomas CC, Richardson LC. Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018. MMWR Morb Mortal Wkly Rep 2020;69:253–259.
2 United States Preventive Services Task Force (USPSTF), "Colorectal Cancer: Screening", May 18, 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening
SOURCE Freenome Holdings, Inc.